Hit ENTER to search or ESC to close

Clinical Studies

We continuously invest in the research on NeuroAiD, the findings are regularly published in specialized journals and released in international conferences.

Our team has worked with world renowned experts in over 20 research centres, and continues to forge academic partnerships to further explore its properties and promising benefits for new indications in neurology.

For more information, feel free to contact our medical team at medical@moleac.com

Ischemic Stroke

NeuroAiD Danqi Piantang Jiaonang Does Not Modify Hemostasis, Hematology, and Biochemistry in Normal Subjects and Stroke Patients.

Participation Size: 64

NeuroAiD in Stroke Recovery.

Participation Size: 10

Ischemic Stroke

A Double-Blind, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of the Traditional Chinese Medicine NeuroAiD (MLC601) in Enhancing Recovery after Stroke (TIERS).

Participation Size: 40

Sponsor: Moleac Pte Ltd.

NeuroAiD (Danqi Piantang Jiaonang), a Traditional Chinese Medicine, in Poststroke Recovery.

Participation Size: 605

Sponsor: Tianjin University of Traditional Chinese Medicine

Traumatic Brain Injury – Neurosurgical pathologies

Case Report on the Use of MLC601 (NeuroAiD) in Neurosurgical Pathologies.

Publication: Yeo TT, et al. Poster WSC Seoul 2010.

Participation Size: 3

Ischemic Stroke

The effect of NeuroAiD (MLC601) on cerebral blood flow velocity in subjects’ post brain infarct in the middle cerebral artery territory.

Participation Size: 80

NeuroAiD (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia.

Participation Size: 40

Sponsor: Moleac Pte. Ltd.

Publication: Ghandehari K, et al. Neural Regen Res 2011. DOI: 10.3969/j.issn.1673-5374.2011.06.003

Ischemic Stroke

The Use of NeuroAiD (MLC601) in Post ischemic Stroke Patients.

Participation Size: 30

Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial.

Participation Size: 150

Sponsor: Shahid Beheshti University

Ischemic Stroke

Chinese Medicine Neuroaid Efficacy on Stroke Recovery: A Double-Blind, Placebo-Controlled, Randomized Study.

Participation Size: 1099

Sponsor: CHIMES Society

Cognitive Disorders & Dementia

Efficacy and Tolerability of MLC601 in Patients with Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.

Publication: Harandi AA, et al. Brit Med Med Res 2013.

Participation Size: 124

Sponsor: Shahid Beheshti University of Medical Sciences

Ischemic Stroke

A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke.

Participation Size: 150

Ischemic Stroke

CHInese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy.

Participation Size: 880

Sponsor: CHIMES Society

Cognitive Disorders & Dementia

Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer’s Disease: A Multicenter, Randomized Controlled Trial.

Participation Size: 264

Ischemic Stroke

NurAiD-II in stroke recovery: scientific reasoning and real-world evidence.

Publication: De Le Cruz Cosme C. International Journal of Clinical Neurosciences and Mental Health 2017.

Cognitive Disorders & Dementia

MLC601 in vascular dementia: an efficacy and safety pilot study.

Participation Size: 81

Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study.

Participation Size: 72

Traumatic Brain Injury – Neurosurgical pathologies

MLC901 (NeuroAiD) for cognition after traumatic brain injury: a pilot randomized clinical trial.

Participation Size: 78

Ischemic Stroke

Predictors of Neurological and Functional Recovery in Patients with Moderate to Severe Ischemic Stroke: The EPICA Study.

Traumatic Brain Injury – Neurosurgical pathologies

Clinical Outcomes of MLC601 (NeuroAiD) in Traumatic Brain Injury: A Pilot Study.

MLC901 for Moderate to Severe Traumatic Brain Injury: Pilot, Randomized, Double-Masked, Placebo-Controlled Trial.

Safety and Use of MLC601/MLC901 (NeuroAiD) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry.

Spinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury.

Participation Size: 26

Sponsor: Moleac Pte. Ltd.

The NeuroAiD Safe Treatment (NeST) Registry: a protocol.

Participation Size: 460

Sponsor: CHIMES Society

The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES).

Participation Size: 103

Sponsor: National University Hospital, Singapore

The Alzheimer’s disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer’s disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial.

Participation Size: 125

Disclaimers: NeuroAiD™ II is a trademark of Moleac. MLC601 and MLC901 are 2 different proprietary formulations which have been shown to be equivalent in pharmacology and are referred as NeuroAiD on this webpage.

Find-out if NeuroAiD is right for you.

Leave your questions to our Customer Care team by clicking on the box below. Always seek advice from your physician.

ASK YOUR QUESTIONS